Caroline Loew - 01 Mar 2024 Form 4 Insider Report for Mural Oncology plc (MURA)

Role: Chief Executive Officer, Director
Signature: /s/ Maiken Keson-Brookes, attorney-in-fact for Caroline Loew
Issuer symbol: MURA
Transactions as of: 01 Mar 2024
Net transactions value: $0
Form type: 4
Filing time: 04 Mar 2024, 17:25:26 UTC
Previous filing: 18 Dec 2023
Next filing: 08 Jul 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MURA	Ordinary Shares	Award	$0	+48,475	+24%	$0.000000	252,922	01 Mar 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MURA	Stock Option (right to buy)	Award	$0	+90,025		$0.000000	90,025	01 Mar 2024	Ordinary Shares	90,025	$5.39	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of ordinary shares issuable under 48,475 restricted stock units ("RSUs"). Each RSU represents the right to receive one ordinary share of the Issuer upon vesting. These RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of March 1, 2024, subject to the reporting person's continued service with the Issuer.
F2	This option was granted on March 1, 2024. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on March 1, 2025 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer.